AngioDynamics, Inc. (NASDAQ:ANGO) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. cut its stake in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 35.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 272,307 shares of the medical instruments supplier's stock after selling 152,801 shares during the period. Assenagon Asset Management S.A. owned about 0.67% of AngioDynamics worth $2,494,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Segall Bryant & Hamill LLC raised its stake in AngioDynamics by 142.7% in the third quarter. Segall Bryant & Hamill LLC now owns 911,443 shares of the medical instruments supplier's stock valued at $7,091,000 after buying an additional 535,958 shares in the last quarter. Millennium Management LLC raised its position in shares of AngioDynamics by 41.9% during the 2nd quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier's stock worth $10,850,000 after acquiring an additional 529,861 shares in the last quarter. Systematic Financial Management LP lifted its stake in AngioDynamics by 14.3% during the third quarter. Systematic Financial Management LP now owns 2,410,346 shares of the medical instruments supplier's stock worth $18,752,000 after purchasing an additional 300,785 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in AngioDynamics by 28.7% in the third quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier's stock valued at $4,304,000 after purchasing an additional 123,271 shares in the last quarter. Finally, Royce & Associates LP increased its stake in AngioDynamics by 10.8% in the third quarter. Royce & Associates LP now owns 986,073 shares of the medical instruments supplier's stock valued at $7,672,000 after purchasing an additional 96,138 shares during the last quarter. 89.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Canaccord Genuity Group lowered their target price on shares of AngioDynamics from $13.00 to $12.00 and set a "buy" rating for the company in a report on Friday, October 4th. HC Wainwright raised their price objective on AngioDynamics from $14.00 to $15.00 and gave the stock a "buy" rating in a report on Friday, January 10th.

AngioDynamics Trading Up 3.2 %

Shares of AngioDynamics stock traded up $0.39 during trading on Thursday, reaching $12.45. The company's stock had a trading volume of 542,834 shares, compared to its average volume of 1,088,431. The company has a 50-day moving average price of $9.05 and a two-hundred day moving average price of $7.80. AngioDynamics, Inc. has a fifty-two week low of $5.26 and a fifty-two week high of $13.13. The firm has a market cap of $503.85 million, a PE ratio of -2.21 and a beta of 0.59.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.07. The business had revenue of $72.90 million during the quarter, compared to analysts' expectations of $70.93 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business's revenue was down .1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.05) earnings per share. On average, analysts predict that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Warren Nighan, Jr. sold 4,060 shares of the stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the completion of the transaction, the senior vice president now directly owns 41,817 shares of the company's stock, valued at approximately $514,767.27. This represents a 8.85 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 5.40% of the company's stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.